442 material Form 8-K filings that 386 companies we cover made with the SEC in March 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
FactSet reported results for the three months ended February 28, 2025, with GAAP revenue up 4.5% to $570.7 million and GAAP diluted EPS up 3.0% to $3.76, while GAAP operating margin fell to 32.5% from 33.3%. The company raised its fiscal 2025 GAAP revenue guidance but lowered its GAAP diluted EPS guidance, and left its adjusted diluted EPS guidance unchanged at $16.80 to $17.40, so the outlook is mixed for shareholders.
GAAP revenue of $570.7 million, up 4.5%; organic revenue of $568.0 million, up 4.0%
GAAP diluted EPS of $3.76, up 3.0%; adjusted diluted EPS of $4.28, up 1.4%
Fiscal 2025 GAAP revenue guidance raised to $2,305 million to $2,325 million from $2,285 million to $2,305 million
Fiscal 2025 GAAP diluted EPS guidance lowered to $14.80 to $15.40 from $15.10 to $15.70
TKO Group Holdings filed recast historical financial statements for fiscal 2023 and 2022 to reflect the Endeavor asset acquisition as if it had closed on January 1, 2022, and to adopt ASU 2023-07 segment reporting. The filing does not update the company's prior annual reports. For shareholders, it shows higher recast revenue but lower operating income and a net loss attributable to TKO Group Holdings for 2023.
Recast 2023 revenue was $3,224.8 million, up from $2,674.0 million in 2022, an increase of 21%.
Recast 2023 operating income was $375.8 million, down from $532.9 million in 2022.
Net loss attributable to TKO Group Holdings, Inc. was $35.2 million for 2023, compared with no such amount for 2022.
The Endeavor asset acquisition closed on February 28, 2025, with total consideration of approximately $3.25 billion plus a $50 million purchase price adjustment.
Five Below reported fourth-quarter fiscal 2024 net sales of $1.39 billion, up 4.0%, but diluted EPS fell to $3.39 from $3.65 and comparable sales declined 3.0%. For fiscal 2025, the company guided to diluted EPS of $3.90 to $4.52, below its fiscal 2024 diluted EPS of $4.60, so shareholders face a mixed picture of higher sales but lower profit.
Q4 net sales rose 4.0% to $1.39 billion, or 7.8% excluding the 53rd week in fiscal 2023; comparable sales fell 3.0%
Q4 diluted EPS was $3.39 versus $3.65; adjusted diluted EPS was $3.48, a 0.6% decline excluding the 53rd week
Fiscal 2024 net sales rose 8.9% to $3.88 billion, but diluted EPS was $4.60 versus $5.41 in fiscal 2023
Fiscal 2025 guidance: net sales of $4.21 billion to $4.33 billion and diluted EPS of $3.90 to $4.52; Q1 diluted EPS of $0.44 to $0.55
Williams-Sonoma reported fourth-quarter fiscal 2024 net revenues of $2.46 billion, up from $2.28 billion a year earlier, with diluted EPS of $3.28 versus $2.72 and a record Q4 operating margin of 21.5%. The company also raised its quarterly dividend 16% to $0.66 per share, and its fiscal 2025 outlook projects net revenues from -1.5% to +1.5% and comparable revenue from flat to +3.0%.
Q4 comparable brand revenue rose 3.1%, and full-year fiscal 2024 comparable brand revenue fell 1.6%.
Q4 diluted EPS was $3.28 versus $2.72 a year earlier; full-year fiscal 2024 diluted EPS was $8.79.
Quarterly dividend increased 16% to $0.66 per share, payable May 24, 2025, to holders of record on April 17, 2025.
Fiscal 2025 outlook: net revenues -1.5% to +1.5%, comparable revenue flat to +3.0%, operating margin 17.4% to 17.8%.
Ollie's reported fourth-quarter fiscal 2024 results on March 19, 2025. Net sales rose 2.8%, but net income fell 10.4% to $68.6 million, or $1.11 per diluted share, from a year earlier, and the quarter included a one-time $5.5 million equity award expense. The Board also approved a new $300 million share repurchase authorization effective through March 31, 2029, and the company guided to fiscal 2025 adjusted earnings of $3.65 to $3.75 per diluted share.
Q4 net sales rose 2.8% to $667.1 million; net income fell 10.4% to $68.6 million, or $1.11 per diluted share, from $1.23.
Fiscal 2024 net income rose 10.1% to $199.8 million, or $3.23 per diluted share, on net sales of $2.272 billion.
The Board approved a new $300 million buyback effective through March 31, 2029; $32.7 million remains on the prior program, which expires March 31, 2026.
Fiscal 2025 outlook: net sales of $2.564 to $2.586 billion, adjusted EPS of $3.65 to $3.75, and 75 new store openings.
General Mills reported fiscal 2025 third-quarter results for the quarter ended February 23, 2025, with net sales down 5% to $4.8 billion and diluted EPS down 4% to $1.12. It also lowered its full-year fiscal 2025 outlook, now expecting organic net sales down 2% to down 1.5% and adjusted operating profit and adjusted diluted EPS down 8% to down 7% in constant currency. For shareholders, this points to weaker sales and profit than the company previously expected, which it attributed to retailer inventory reductions and a slowdown in snacking categories.
Third-quarter net sales were $4.8 billion, down 5%; organic net sales were also down 5%, including about 4 points of retailer inventory reductions and the expected reversal of certain second-quarter timing items.
Diluted EPS was $1.12, down 4%; adjusted diluted EPS was $1.00, down 15% in constant currency.
Full-year fiscal 2025 adjusted operating profit and adjusted diluted EPS are now expected to be down 8% to down 7% in constant currency, compared with the previous down 4% to down 2%.
Holistic Margin Management is expected to deliver at least 5% cost of goods sold savings in fiscal 2026, about $600 million, and new cost-savings initiatives target at least $100 million.
Signet reported fourth-quarter fiscal 2025 sales of $2.4 billion, down 5.8%, with same store sales down 1.1% and diluted EPS of $2.30 versus $11.75 a year earlier, after $200.7 million in non-cash impairment charges. The company initiated fiscal 2026 guidance for sales of $6.53 billion to $6.80 billion and adjusted diluted EPS of $7.31 to $9.10, and announced a new "Grow Brand Love" strategy and reorganization. The board also raised the quarterly common dividend 10% to $0.32 per share.
Q4 sales were $2,352.6 million, down $145.0 million or 5.8%; same store sales fell 1.1%.
Q4 diluted EPS was $2.30 versus $11.75; adjusted diluted EPS was $6.62 versus $6.73.
Fiscal 2026 guidance: sales of $6.53 billion to $6.80 billion; same store sales (2.5%) to +1.5%; adjusted diluted EPS of $7.31 to $9.10 versus $8.94 in fiscal 2025.
Quarterly dividend of $0.32 per share, a 10% increase, payable May 23, 2025 to holders of record April 25, 2025.
Liquidia reported full-year 2024 revenue of $14.0 million, down from $17.5 million, and a net loss of $130.4 million, or $1.66 per share, versus a net loss of $78.5 million, or $1.21 per share, in 2023. Cash and cash equivalents rose to $176.5 million at year-end, and the company amended its HCRx financing agreement to provide up to an additional $100 million, with $25.0 million received at closing. Shareholders face wider losses and lower revenue, while the company awaits possible final FDA approval of YUTREPIA after regulatory exclusivity expires on May 23, 2025.
Revenue fell to $14.0 million from $17.5 million, mainly due to lower sales quantities tied to limited availability of pumps for Treprostinil Injection.
General and administrative expenses rose to $81.6 million from $44.7 million; research and development expenses rose to $47.8 million from $43.2 million.
Net loss was $130.4 million, or $1.66 per share, compared with $78.5 million, or $1.21 per share, in 2023.
The HCRx amendment provides up to $100 million in three tranches; Liquidia received $25.0 million at closing.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.